Strides Pharma Science Limited

STAR

INE939A01011

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:43:50 2024-05-10 am EDT			5-day change	1st Jan Change
843 ^INR	+1.17%		-4.91%	+29.85%

May. 10	Market Heavyweights Lifts Indian Equities to End Week Higher	MT
May. 10	Strides Pharma Arm Gets US FDA's Approval for Generic Drug for Hypocalcemia	MT

Strides Arcolab Ltd. Appoints S. Abhaya Kumar as Executive Director

November 20, 2015 at 03:27 am EST

Strides Arcolab Ltd. appointed S. Abhaya Kumar as Executive Director of the company with effect from November 19, 2015. Mr. Abhaya was the founder and managing director of erstwhile Shasun Pharmaceuticals.

Latest news about Strides Pharma Science Limited

Market Heavyweights Lifts Indian Equities to End Week Higher	May. 10	MT
Strides Pharma Arm Gets US FDA's Approval for Generic Drug for Hypocalcemia	May. 10	MT
Strides Pharma Science Limited Approves Appointment of Ameet P Hariani as Independent Director	Apr. 30	CI
Strides Pharma Science Gets US FDA Nod for Fluoxetine Tabs	Apr. 09	MT
Transcript : Strides Pharma Science Limited, Q3 2024 Earnings Call, Jan 30, 2024	Jan. 30
Strides Pharma Science Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Jan. 30	CI
Strides Pharma Science Arm Gets US FDA Nod for Pregabalin Capsules	Jan. 25	MT
Strides Pharma Science's Swiss Unit to Sell Entire Stake in Eris Pharma	Jan. 11	MT
Strides Pharma Science Arm Acquires Additional 25% Stake in Neviton Softech	Jan. 08	MT
Strides Pharma Science Acquires Minority Stake in Two Renewable Energy Companies	Jan. 02	MT
Strides Pharma Science Subsidiary Secures Credit Facility Worth INR319 Million	Dec. 21	MT
India's Nifty set to open at new record highs for second session in a row	Dec. 03	RE
Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules	Dec. 01	CI
Strides Pharma Unit Gets US FDA Approval for Generic Bowel Prep Kit Solution	Nov. 22	MT
Strides Pharma Global Pte. Limited Receives USFDA Approval for Generic Suprep®? Bowel Prep Kit	Nov. 22	CI
Strides Pharma Science Arm Gets US FDA's Nod for Generic Seizure Treatment	Nov. 21	MT
Strides Pharma Science Appoints COO	23-10-30	MT
Transcript : Strides Pharma Science Limited, Q2 2024 Earnings Call, Oct 30, 2023	23-10-30
Strides Pharma Science Limited Announces Change in Management	23-10-30	CI
Strides Pharma Science Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	23-10-30	CI
Strides Pharma Science to Sell Singapore Manufacturing Site for $15 Million	23-10-30	MT
Strides Pharma Arm Gets US FDA Nod for HIV Treatment Drug	23-10-04	MT
Strides Pharma Unit Gets US FDA Approval for Generic HIV Drugs	23-10-04	MT
Strides Pharma Global Pte. Limited Receives USFDA Approval for Efavirenz, Emtricitabine & Tenofovir Disoproxil Fumurate Tablets	23-10-04	CI
INDIA STOCKS-Indian shares seen opening lower amid sustained foreign selling	23-09-25	RE

Chart Strides Pharma Science Limited

Duration

Period

More charts

Company Profile

Strides Pharma Science Limited is an India-based pharmaceutical company. The Company is focused on the development and manufacture of IP-led niche and pharmaceutical products. The Company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The Company manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. It has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). It is also engaged in manufacturing soft gelatin capsules. It develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.

Sector

Pharmaceuticals

Calendar

2024-05-22 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Strides Pharma Science Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

843 INR

Average target price

830.5 INR

Spread / Average Target

-1.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
STRIDES PHARMA SCIENCE LIMITED	+29.85%	928M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.27B
OTSUKA HOLDINGS CO., LTD.	+24.52%	22.92B
SANDOZ GROUP AG	+20.29%	15.43B
CIPLA LIMITED	+7.48%	12.95B
ZYDUS LIFESCIENCES LIMITED	+42.51%	11.83B
ONO PHARMACEUTICAL CO., LTD.	-8.84%	6.91B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.13%	5.55B

Generic Pharmaceuticals

Strides Pharma Science Limited

Equities

STAR

INE939A01011

Pharmaceuticals

Strides Arcolab Ltd. Appoints S. Abhaya Kumar as Executive Director

Latest news about Strides Pharma Science Limited

Chart Strides Pharma Science Limited

Company Profile

Income Statement Evolution

Ratings for Strides Pharma Science Limited

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Generic Pharmaceuticals